Matthew Perrone, The Associated Press

Matthew Perrone

The Associated Press

Washington, DC, United States

Contact Matthew

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

Recent:
  • KTVE - KARD
  • FOX 29
  • KSN News Wichita
  • The Seattle Times
  • Boston 25 News
  • The Hill
  • Fox5NY
  • KEYT NewsChannel 3
  • FOX26Houston
  • Pioneer Press
  • Orlando Sentinel
  • WJHL
  • FOX 5 Atlanta
  • The Associated Press
  • WNYT NewsChannel 13
  • NBC KSNV News 3
Past:
  • ABC News
  • CBS 8 San Diego
  • The Denver Post
  • PIX11
  • TIME.com
  • Cashay
  • Winnipeg Free Press
  • AOL.com
  • FOX 5 DC
  • Star Tribune
  • and more…

Recent articles by Matthew:

ALS drug wins FDA approval despite questionable data

WASHINGTON (AP) — A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines. The Food and Drug Administration approved the drug from Amylyx Pharmaceuticals based on results from one small, mid-stage study in […] → Read More

Baby formula shortage: US to allow long-term foreign imports to prevent repeat

For decades, the U.S. formula industry has been dominated by a handful of companies, excluding similar products from overseas. A new plan will change that. → Read More

US outlines plan for long-term baby formula imports

WASHINGTON (AP) — U.S. regulators on Friday unveiled their plan to allow foreign baby formula manufacturers to stay on the market long term, an effort to diversify the nation’s tightly concentrated industry and prevent future shortages. The Food and Drug Administration said recent entrants to the U.S. market will have until October 2025 to make […] → Read More

US outlines plan for long-term baby formula imports

U.S. regulators have revealed their plan to allow foreign baby formula manufacturers to stay on the market long term. → Read More

ALS drug wins FDA approval despite questionable data

U.S. health officials have approved a much-debated drug to treat the deadly illness known as Lou Gehrig's disease → Read More

ALS drug wins FDA approval despite questionable data

WASHINGTON (AP) — A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind gov… → Read More

ALS drug wins FDA approval despite questionable data

U.S. health officials have approved a much-debated drug to treat the deadly illness known as Lou Gehrig's disease. → Read More

Baby formula shortage: FDA concedes delays after whistleblower complaint

A 10-page report from the agency offers its first formal account of the factors that led to the ongoing shortage. → Read More

FDA concedes delays in response to baby formula shortage

FDA concedes delays in response to baby formula shortage → Read More

US health officials warn monkeypox could mutate to resist antiviral drug Tpoxx

U.S. health officials are warning doctors against overusing the lone drug available to treat monkeypox. Federal health officials say that even a small mutation in the virus could leave the drug ineffective. → Read More

Juul to pay nearly $440M to settle states’ teen vaping probe

HARTFORD, Conn. (AP) — Electronic cigarette maker Juul Labs has agreed to pay nearly $440 million to settle a two-year investigation by 33 states into the marketing of its high-nicotine vapin… → Read More

Juul to pay nearly $440M to settle states’ teen vaping probe

The settlement, which includes numerous restrictions on how Juul can market its products, resolves one of the biggest legal threats facing the beleaguered company, which still faces nine separate lawsuits from other states and hundreds of personal lawsuits. → Read More

Juul to pay nearly $440M to settle states’ teen vaping probe

HARTFORD, Conn. (AP) — Electronic cigarette maker Juul Labs has agreed to pay nearly $440 million to settle a two-year investigation by 33 states into the marketing of its high-nicotine vaping products, which have long been blamed for sparking a national surge in teen vaping. Connecticut Attorney General William Tong announced the deal Tuesday on […] → Read More

Juul to pay nearly $440M to settle states’ teen vaping probe

HARTFORD, Conn. (AP) — Electronic cigarette maker Juul Labs has agreed to pay nearly $440 million to settle a two-year investigation by 33 states into the marketing of its high-nicotine vaping products, which have long been blamed for sparking a national surge in teen vaping. Connecticut Attorney General William Tong announced the deal Tuesday on […] → Read More

Juul to pay nearly $440 million in states' teen vaping settlement

Juul's product has long been blamed for sparking a national surge in teen vaping. → Read More

Juul to pay nearly $440M to settle states' teen vaping probe

HARTFORD, Conn. (AP) — Electronic cigarette maker Juul Labs has agreed to pay nearly $440 million to settle a two-year investigation by 33 states into the marketing of its high-nicotine vaping products, which have long been blamed for sparking a national surge in teen vaping. → Read More

Juul to pay nearly $440M to settle states' teen vaping probe

Electronic cigarette maker Juul Labs has agreed to pay nearly $440 million to settle a multi-state investigation into its vaping products, which have long been blamed for sparking a national surge in teen vaping. Connecticut announced the deal Tuesday on behalf of the 33 states plus Puerto Rico. Attorneys general joined together in 2020 to probe Juul’s early promotions, including product… → Read More

Juul to pay nearly $440M to settle states' teen vaping probe

Electronic cigarette maker Juul Labs will pay nearly $440 million to settle a two-year investigation by 33 states into the marketing of its high-nicotine vaping → Read More

FDA still skeptical of ALS drug ahead of high-stakes meeting

WASHINGTON (AP) — Federal health regulators remain unconvinced about the benefits of a closely watched experimental drug for the debilitating illness known as Lou Gehrig’s disease, even as they pre… → Read More

Study: Pfizer COVID pill showed no benefit in younger adults

WASHINGTON (AP) — Pfizer's COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors, according to a large study published Wednesday. → Read More